Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inh

Journal Article · · Bioorg. Med. Chem. Lett.
Research Organization:
Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
Sponsoring Organization:
DOE - Office Of Science; INDUSTRY
OSTI ID:
1837295
Journal Information:
Bioorg. Med. Chem. Lett., Journal Name: Bioorg. Med. Chem. Lett. Journal Issue: (10) Vol. 28
Country of Publication:
United States
Language:
ENGLISH

References (19)

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity journal November 2016
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases: Miniperspective journal January 2014
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) journal August 2018
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 journal April 2010
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis journal November 2013
The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications journal April 2019
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165 journal July 2019
Stereochemistry of the Kulinkovich Cyclopropanation of Nitriles journal June 2009
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases journal January 2019
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis journal November 2007
Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions journal October 2017
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841) journal May 2018
Predicting Clearance in Humans from In Vitro Data journal February 2011
Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease journal April 2007
Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches journal May 2009
Development of a new permeability assay using low‐efflux MDCKII cells journal November 2011
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS) journal July 2015
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms journal April 2010
ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling journal May 2014

Similar Records

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inh
Journal Article · Fri May 01 00:00:00 EDT 2020 · Bioorg. Med. Chem. Lett. · OSTI ID:1833659

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1
Journal Article · Thu Apr 30 20:00:00 EDT 2020 · Bioorganic and Medicinal Chemistry · OSTI ID:1703820

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1
Journal Article · Thu Dec 15 19:00:00 EST 2016 · ACS Medicinal Chemistry Letters · OSTI ID:1404997

Related Subjects